Tradestie Institutional Equity Comparison Engine

XOMA vs GERN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

XOMA Overall Edge

XOMA Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to XOMA Royalty Corporation Common Stock (XOMA) driven by superior Valuation, Growth & Margin, Momentum & Technical while GERN counters with relative strength in Options & Structure. Fundamentally, XOMA trades at 21.5x Forward P/E with -3.9% operating margin (-22.6% YoY revenue) versus GERN at 51.0x Forward P/E and -7.2% operating margin (+27.4% YoY). In options structure, XOMA sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against GERN sits in BREAKDOWN (15th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner XOMA
XOMA 21.5x vs GERN 51.0x Fwd P/E
Growth & Margin Winner XOMA
Op Margin -3.9% vs -7.2% ยท YoY -22.6% vs +27.4%
Momentum & Technical Winner XOMA
1Y +44.0% vs -16.7% ยท 52W Pos 78% vs 10%
Options & Structure Winner GERN
UNCLASSIFIED (100th %ile IV) vs BREAKDOWN (15th %ile IV)
XOMA NASDAQ
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
1M Return -3.81%
1Y Return +43.98%
Forward P/E 21.5x
Unified AI Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
GERN NASDAQ
Geron Corp
Pharmaceutical Preparations
$0.96
-0.95% 1D
Market Cap $640.4M
1M Return -18.14%
1Y Return -16.71%
Forward P/E 51.0x
Unified AI Score
60.8 / 100 BUY
Tech 69.0 Fund 70.0 Flow 71.0 Mom 68.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: XOMA +43.98% GERN -16.71% Spread: +1.12 pp (XOMA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
XOMA TTM Op. Margin: -3.9% GERN TTM Op. Margin: -7.2%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs GERN. Trailing 12-month operating profitability (XOMA -3.9% vs GERN -7.2%) and valuation multiples (XOMA 21.5x vs GERN 51.0x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: XOMA (8) vs GERN (2)
Institutional Metric XOMA GERN Criterion Row Winner
Market Capitalization Scale $781.8M $640.4M Larger Scale XOMA
Trailing P/E Ratio Valuation 28.2x 51.0x Lower Multiple XOMA
Forward P/E Ratio Valuation 21.5x 51.0x Lower Multiple XOMA
Revenue Growth (YoY) Growth -22.6% +27.4% Higher Growth GERN
Operating Margin (TTM) Profitability -3.9% -7.2% Higher Margin XOMA
Net Profit Margin Profitability 69.6% -22.0% Higher Margin XOMA
Return on Equity (ROE) Capital Efficiency 34.2% -20.1% Higher ROE XOMA
52-Week Range Position Momentum 78% ($22โ€“$45) 10% ($1โ€“$2) Stronger Trend XOMA
Beta / 30D Volatility Risk Regime 0.68ฮฒ ยท 37% Vol 1.52ฮฒ ยท 101% Vol Lower Realized Risk XOMA
Unified Institutional Score Composite Signal 55.8 / 100 (HOLD) 60.8 / 100 (BUY) Higher Composite GERN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full XOMA vs GERN Buy Guide
XOMA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live XOMA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GERN BREAKDOWN
72d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 15th %ile
IV Regime Compressed (<25th %ile)
Live GERN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither XOMA nor GERN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.